Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.70099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Hongsheng Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Liver Cirrhosis, Nucleosides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province for Distinguished Young Scholar, Natural Science Foundation Team Project of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The applicability of the Agile 3+ score to patients with CHB–MASLD receiving antiviral therapy remains unexplored. Our objective was to explore the diagnostic and prognostic performances of the Agile 3+ score in patients with CHB–MASLD.
Methods
This retrospective cohort study included consecutively enrolled patients with CHB and concurrent MASLD from 2014 to 2020. In Part 1, we evaluated the performance of the Agile 3+ score in predicting advanced fibrosis. In Part 2, the Agile 3+ score was applied to a follow‐up cohort to assess its correlation with liver‐related events.
Results
Among the 2492 patients evaluated by vibration‐controlled transient elastography, 103 patients with CHB and hepatic steatosis were included in the biopsy cohort, and 716 patients were included in the follow‐up cohort. The Agile 3+ score had the highest AUROC of 0.916 for the prediction of advanced fibrosis, outperforming the FIB‐4 score (0.845), NFS (0.838), and APRI (0.726). In predicting liver‐related events (LREs), the AUROC of the Agile 3+ score was also significantly higher (0.795 at 3 years, 0.809 at 5 years, and 0.834 at 8 years) than those of the other noninvasive tests. When the recommended cutoffs (0.451 and 0.679) were applied for MASLD risk stratification, the high‐risk group (HR = 13.61) and intermediate‐risk group (HR = 3.53) had significantly greater risks of LREs than the low‐risk group.
Conclusion
In patients with CHB and concurrent MASLD receiving antiviral therapy, the Agile 3+ score effectively identifies advanced fibrosis and predicts LRE risk, supporting its clinical utility in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, Guangdong, China.
- Department of Emergency, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, People's Republic of China.
- Department of Pathology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
- Department of Pathology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Jianhao Wu, Jianning Chen, Bin Wu, Yidong Yang
Förderung
- Natural Science Foundation of Guangdong Province for Distinguished Young Scholar
- Natural Science Foundation Team Project of Guangdong Province
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Yu, H., Wu, J., Li, M., Hu, C., Ren, Y., Jiang, H., Huang, Y., Lei, Y., Chen, J., Wu, B., & Yang, Y. (2025). Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70099
Vancouver
Yu H, Wu J, Li M, Hu C, Ren Y, Jiang H, et al. Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.70099
BibTeX
@article{Yu2025,
author = {Yu, Hongsheng and Wu, Jianhao and Li, Mingkai and Hu, Can and Ren, Yuexiang and Jiang, Hao and Huang, Yinan and Lei, Yiming and Chen, Jianning and Wu, Bin and Yang, Yidong},
title = {Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.70099}
}
EUVIMED